Fibrosing rheumatic diseases (scleroderma, MCTD, IgG4-related disease, scleroderma mimics)
Christopher Denton, MD;PhD
University College London
Northwood, United Kingdom
Disclosure(s): AbbVie: Consultant (Ongoing); Acceleron: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); Arxx Therapeutics: Grant/Research Support (Ongoing); Bayer: Consultant (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Certa: Consultant (Ongoing); Corbus: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); CSL Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); EMD Serono: Consultant (Ongoing); GlaxoSmithKline: Consultant (Ongoing), Grant/Research Support (Ongoing); Horizon Therapeutics: Consultant (Ongoing); Inventiva: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Consultant (Ongoing); Roche: Consultant (Ongoing); Sanofi: Consultant (Ongoing); Servier: Grant/Research Support (Ongoing), Grant/Research Support (Ongoing)
Scleroderma renal crisis is an uncommon, yet extremely morbid complication of scleroderma. Recognizing, treating, and preventing scleroderma renal crisis continues to evolve with new studies showing novel biomarkers and potential for new agents to treat patients. This session will provide case-based questions to help describe to the approach and management of scleroderma renal crisis.
Speaker: Christopher Denton, MD;PhD – University College London